Dasari Bobby V M, Line Pal-Dag, Sapisochin Gonzalo, Hibi Taizo, Bhangui Prashant, Halazun Karim J, Shetty Shishir, Shah Tahir, Magyar Christian T J, Donnelly Conor, Chatterjee Dev
Department of Liver Transplantation and HBP Surgery, Queen Elizabeth Hospital, Birmingham, UK.
Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
BJS Open. 2025 May 7;9(3). doi: 10.1093/bjsopen/zraf034.
Liver transplantation for cancer indications has gained momentum in recent years. This review is intended to optimize the care setting of liver transplant candidates by highlighting current indications, technical aspects and barriers with available solutions to facilitate the guidance of available strategies for healthcare professionals in specialized centres.
A review of the most recent relevant literature was conducted for all the cancer indications of liver transplantation including colorectal cancer liver metastases, hilar cholangiocarcinoma, intrahepatic cholangiocarcinoma, neuroendocrine tumours, hepatocellular carcinoma and hepatic epitheloid haemangioendothelioma.
Transplant benefit from the best available evidence, including SECA I, SECA II, TRANSMET studies for colorectal liver metastases, various preoperative protocols for cholangiocarcinoma patients, standard, extended selection criteria for hepatocellular carcinoma and neuroendocrine tumours, are discussed. Innovative approaches to deal with organ shortages, including machine-perfused deceased grafts, living donor liver transplantation and RAPID procedures, are also explored.
Cancer indications for liver transplantation are here to stay, and the selection criteria among all cancer groups are likely to evolve further with improved prognostication of tumour biology using adjuncts such as radiomics, cancer genomics, and circulating DNA and RNA status. International prospective registry-based studies could overcome the limitations of smaller patient cohorts and lack of level 1 evidence.
近年来,因癌症适应症进行的肝移植有了发展势头。本综述旨在通过强调当前适应症、技术方面以及现有解决方案所面临的障碍,来优化肝移植候选者的护理环境,以便为专业中心的医疗保健专业人员提供可用策略的指导。
对肝移植所有癌症适应症的最新相关文献进行了综述,包括结直肠癌肝转移、肝门胆管癌、肝内胆管癌、神经内分泌肿瘤、肝细胞癌和肝上皮样血管内皮瘤。
讨论了从现有最佳证据中得出的移植益处,包括用于结直肠癌肝转移的SECA I、SECA II、TRANSMET研究,胆管癌患者的各种术前方案,肝细胞癌和神经内分泌肿瘤的标准、扩展选择标准。还探讨了应对器官短缺的创新方法,包括机器灌注的尸体供肝、活体肝移植和快速程序。
肝移植的癌症适应症将持续存在,随着使用放射组学、癌症基因组学以及循环DNA和RNA状态等辅助手段对肿瘤生物学的预后评估得到改善,所有癌症组别的选择标准可能会进一步演变。基于国际前瞻性登记处的研究可以克服较小患者队列的局限性以及缺乏一级证据的问题。